MedPacto Valuation

Is A235980 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of A235980 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate A235980's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate A235980's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for A235980?

Key metric: As A235980 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for A235980. This is calculated by dividing A235980's market cap by their current book value.
What is A235980's PB Ratio?
PB Ratio	2.7x
Book	₩57.68b
Market Cap	₩156.99b

A235980 key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-3.6x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does A235980's PB Ratio compare to its peers?

The above table shows the PB ratio for A235980 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	6x
A288330 Bridge Biotherapeutics	14.5x	n/a	₩143.4b
A115180 Qurient	3.3x	n/a	₩155.2b
A293780 AptaBio Therapeutics	3.1x	n/a	₩154.1b
A217330 Cytogen	3.1x	n/a	₩169.6b
A235980 MedPacto	2.7x	n/a	₩157.0b

Price-To-Book vs Peers: A235980 is good value based on its Price-To-Book Ratio (2.7x) compared to the peer average (6x).

Price to Book Ratio vs Industry

How does A235980's PB Ratio compare vs other companies in the KR Biotechs Industry?

5 Companies	Price / Book	Estimated Growth	Market Cap
A377740 BioNote	0.3x	n/a	US$344.40m
A950210 Prestige BioPharma	0.4x	n/a	US$138.51m
A109960 AP Healthcare	0.3x	n/a	US$68.18m
A950220 NeoImmuneTech	0.4x	n/a	US$17.18m

5 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: A235980 is expensive based on its Price-To-Book Ratio (2.7x) compared to the KR Biotechs industry average (2.5x).

Price to Book Ratio vs Fair Ratio

What is A235980's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

A235980 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	2.7x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate A235980's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Hugel

₩3.0t

Develops and manufactures biopharmaceuticals in South Korea and internationally.

A145020

₩273,500.00

0.9%

75.3%

J2KBIO

₩52.9b

A bio venture company, provides active ingredients for cosmetics, functional food, and household products from natural materials and microbial fermentation.

A420570

₩9,260.00

-5.8%

n/a

Medy-Tox

₩883.1b

Operates as a biopharmaceutical company in South Korea.

A086900

₩131,200.00

1.7%

-39.0%